Last reviewed · How we verify

NCT04148599

Effect of IV Infusion of Lidocaine Compared to IV Infusion of Dexmedetomidine on Proinflammatory Cytokines

Completed Phase 3 Last updated 3 August 2020
What this trial tests

Phase 3 trial testing dexmedetomidine infusion in Inflammatory Response in 54 participants. Completed in 13 June 2020.

Timeline
2 January 2018
Primary endpoint
10 June 2020
13 June 2020

Quick facts

Lead sponsorNorma Osama Abdalla Zayed
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment54
Start date2 January 2018
Primary completion10 June 2020
Estimated completion13 June 2020
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Norma Osama Abdalla Zayed

Who can join

Adults 18 to 60, any sex, with Inflammatory Response. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to compare between intravenous infusion of dexmedetomidine and intravenous infusion of lidocaine in reduction of proinflammatory cytokines as IL-6 and TNF-α, some stress reactions (serum insulin and serum lactate),and postoperative analgesic requirements in patients undergoing surgery for pelviabdominal cancers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Trial watch: dexmedetomidine in cancer therapy.
    Carnet Le Provost K, Kepp O, Kroemer G, Bezu L. · · 2024 · cited 24× · PMID 38481729 · DOI 10.1080/2162402x.2024.2327143

Verify or expand the search:

Other trials of dexmedetomidine infusion

Trials testing the same drug.

Other recruiting trials for Inflammatory Response

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04148599.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing